Introduction
Neuroendocrine tumors of the lung constitute a distinct subset of neoplasms , and represent a spectrum of tumors that share morphological, immunohistological and molecular characteristics. These include morphological features of organoid nesting, palisading and rosette-like structures, the expression of neuroendocrine markers (synaptophysin and CD56/NCAM), achaete-scute homolog-1 and Bcl-2. However, the clinical behaviors of these tumors are quite different. At one edge of the spectrum, small cell carcinoma (SCLC), is one of the most aggressive types of human cancers. At the other end, are clinically indolent carcinoid tumors, of which the 5-year survival rates are over 95%. Recently, attention has been directed to atypical carcinoid and large cell neuroendocrine cell carcinoma (LCNEC), since they represent an intermediate part of the spectrum (Przygodzki et al., 1996; Travis et al., 1991 Travis et al., , 1999 . These tumors may represent individual steps of progression, because p53 mutations and other genetic alterations accumulate in accordance with tumor grade from typical carcinoid to SCLC. In contrast, recent evidence supports the notion that some of these tumors are individually distinct entities, and that they simply share neuroendocrine features (Anbazhagan et al., 1999; Onuki et al., 1999; Sampietro et al., 2000) . Menin is specifically mutated in typical and in atypical carcinoid (Debelenko et al., 1997a (Debelenko et al., , 2000 Haruki et al., 2000) , and p16 involvement within G1/S regulation is rather frequent in LCNEC, in contrast to the uniform inactivation of Rb in SCLC (Dosaka-Akita et al., 2000; Gouyer et al., 1998) .
Neuroendocrine tumors can arise in non-pulmonary tissue. Carcinoid tumor is more common in the gastrointestinal tract than in the pulmonary region (Godwin, 1975) , while carcinoid occasionally develops in the larynx, ovary, thymus and gallbladder. Carcinoid of the foregut (pulmonary, thymus, stomach, duodenum and pancreas) may differ from that of the midgut and hindgut in terms of embryonic origin, function, biological behavior and the molecular mechanism involved (Debelenko et al., 1997b; Williams and Sandler, 1963) . Small cell carcinoma can also arise in the bladder, uterine cervix, esophagus, large intestine, ovary, pancreas, prostate, stomach and thymus. The morphological features as well as clinical aggressiveness are quite similar to those of SCLC (Galanis et al., 1997; Ibrahim et al., 1984; Murren et al., 2001) , but ordinary carcinoma, such as squamous cell carcinoma and adenocarcinoma, presents together with small cell carcinoma rather often.
The present study examines the unique 14-3-3s proteins. The 14-3-3 series of proteins comprise a family of eukaryotic regulatory molecules that are highly conserved among species. At least seven isoforms have been identified, among which, 14-3-3s, was originally described under several names and from different viewpoints. The 14-3-3s was originally cloned as a molecule, of which expression levels were remarkably reduced in breast cancer cell lines compared with normal mammary epithelial cells. It was therefore named human mammary epithelial marker-1/HME1 (Prasad et al., 1992) . The molecule was then detected as an abundant protein in stratified keratinizing epithelium and was termed stratifin (Vellucci et al., 1995) . Subsequent studies have suggested that 14-3-3s enhances protein kinase C activity, resulting in the terminal differentiation of keratinocytes in cooperation with histone phosphorylation (Dellambra et al., 1995; Leffers et al., 1993) . Indeed, 14-3-3s is up-regulated with differentiation, accompanied by withdrawal of the stem cell marker, p63 (Pellegrini et al., 2001) . In 1997, Hermeking et al. (1997) found that 14-3-3s is induced by g irradiation and by other DNA-damaging agents in a p53-dependent fashion, and that exogenous expression of 14-3-3s causes G2 arrest in a colorectal cancer cell line (HCT116). Later studies revealed that 14-3-3s sequesters Cdc2/cyclin B1 complex in the cytoplasm, which prevents entry into the mitotic phase, thus causing mitotic catastrophe (Chan et al., 1999; Lopez-Girona et al., 1999) . Therefore, in terms of the regulatory role in G2/M checkpoint and suggestive association with the carcinogenesis of a large number of tumors (Dhar et al., 2000; Ferguson et al., 2000; Umbricht et al., 2001; Vercoutter-Edouart et al., 2001 ), 14-3-3s has recently received a considerable research focus.
We recently reported that 14-3-3s is frequently inactivated in lung cancer cell lines . We also noted that the decreased expression of 14-3-3s was confined to SCLC and a part of large cell carcinoma, that showed histological type-specific alteration in lung cancers. Here, we examined over 200 carcinomas with respect to neuroendocrine tumors. The results indicated that decreased expression of 14-3-3s is closely associated with neuroendocrine features despite differences in other alterations including p53 mutations, changes in G1-checkpoint molecules (Rb or p16), proliferating activity, and ploidy pattern as well as clinical response to chemotherapy. Thus, we concluded that decreased 14-3-3s expression is commonly involved in the neoplastic transformation of neuroendocrine tumors.
Results
Decreased 14-3-3s expression in pulmonary neuroendocrine tumors
We reported that 14-3-3s is frequently inactivated in SCLC but not in NSCLC . We also found 14-3-3s inactivation in a part of large cell carcinoma. Detailed morphological and immunohistological analysis revealed that the tumor was categorized into large cell neuroendocrine carcinoma (LCNEC) of the lung. We therefore examined the entire spectrum of pulmonary neuroendocrine tumors. The results (Table  1) showed that 14-3-3s expression was decreased in majority of the neuroendocrine tumors (24 out of 28, 86%). This was found not only in SCLC (15 out of 18, 83.3%), but also in the other categories of neuroendocrine tumors, including 5 out of 5 typical carcinoid, 2 out of 2 atypical carcinoid and 5 out of 7 LCNEC (Figure 1a,b) . However, 14-3-3s expression in NSCLC was highly contrasted to that in neuroendocrine tumors. All the subtypes of NSCLC (73 out of 74, 99%), including 38 adenocarcinomas (Figure 1c ), 23 squamous cell carcinomas and 13 large cell carcinomas, maintained the 14-3-3s expression at a level equal to that of normal cells, with the single exception of the large cell carcinoma. The difference was statistically significant (P50.01 by the w 2 test). This sharp demarcation by 14-3-3s is the superior marker of neuroendocrine differentiation. With regard to the association with p53 status, the expression was decreased in both typical carcinoid and SCLC even though p53 were abnormal in 71% of SCLC, but normal in all carcinoids examined. The status of p53 did not affect 14-3-3s expression in NSCLC. Among the 42 NSCLCs with known p53 status, 18 with mutated p53 expressed 14-3-3s in a manner similar to that of NSCLCs with wild type p53. In terms of subcellular localization of 14-3-3s, both nuclear and cytoplasmic signals were observed in most of the expressing tumors, while nuclear signals were less frequent. Proliferating activity, clinical behavior and RB status was not associated with the expression status of 14-3-3s within or between the spectrum of the (Figure 1d ). Therefore, we concluded that only one neuroendocrine feature among the various alterations was correlated with decreased expression of 14-3-3s.
Dense DNA methylation specific for neuroendocrine tumors
As shown in the previous paper , the expression of 14-3-3s in SCLC in vitro was inactivated by hypermethylation of the 14-3-3s promoter. Because low-grade neuroendocrine tumors such as carcinoid exhibit infrequent genetic alterations, we examined whether promoter hypermethylation contributes to the pathogenesis in vivo of the low-grade tumor as well as SCLC through the examination of 14-3-3s methylation status. Overall, the per cent methylation was significantly higher in neuroendocrine tumors than in NSCLC. An average 63.7% and 31.3% of CpG sites examined were methylated in neuroendocrine tumors and in NSCLC, respectively (P50.01 by unpaired t-test). Dense methylation defined as over 75% of CpG sites methylated, was specific to neuroendocrine tumors, and present in 6 out of 13 neuroendocrine tumors, although none of the NSCLC Figure 1 Expression of 14-3-3s. Expression of 14-3-3s is decreased in tumor cells of typical carcinoid (a) and LCNEC (b), in contrast to positively stained normal bronchial basal cells (center in a) and reactive type II pneumocytes (left half in b). Pulmonary adenocarcinoma (c) expressed 14-3-3s like bronchial basal cells. In combined small cell and adenocarcinoma, only tubular adenocarcinoma portion expresses 14-3-3s (d). Like pulmonary neuroendocrine tumors, 14-3-3s demarcates colon carcinoid tumor from normal crypts (e) and small cell carcinoma of the esophagus (f) from normal squamous epithelium Down-regulated 14-3-3s expression in neuroendocrine tumors Y Yatabe et al were densely methylated. In seven neuroendocrine tumors and nine NSCLCs, the per cent methylation ranged from 15.6 to 62.2%, and from 11.1 to 62.2%, respectively. In these tumors, the methylation patterns were mosaic of extensively methylated and unmethylated alleles ( Figure 2 ). None of the alleles in the last two NSCLC was methylated, but this was not observed in any of the neuroendocrine tumors.
Decreased 14-3-3s expression is a general feature of neuroendocrine tumors
To determine whether expression of 14-3-3s in neuroendocrine tumors is decreased only in the lung, we examined 14-3-3s expression in the 123 nonpulmonary cancers listed in Table 2 . Of 20 neuroendocrine tumors (nine carcinoid and 11 small cell carcinoma), 14-3-3s expression was also decreased in 17 (85%). In contrast, 79 (77%) of 103 nonneuroendocrine tumors expressed the 14-3-3s at a level equal to that of normal cells. The difference between the neuroendocrine and non-neuroendocrine tumors was statistically significant (P50.001 by w 2 test, Figure  1e ,f). Because 14-3-3s was originally cloned as an abundant acidic human keratinocyte protein, we also compared expression between adenocarcinoma and squamous cell carcinoma. All of the squamous cell carcinomas except one expressed high levels of 14-3-3s, whereas 29% of adenocarcinomas was negative for 14-3-3s. Notably, frequency of expression in adenocarcinoma tended to be associated with the expression feature of corresponding normal tissue. In the stomach and colon (Group 1), the overlying epithelium uniformly expressed 14-3-3s among the epithelial layers (Figure 1e ), and most of the adenocarcinomas in that region were positive for 14-3-3s. In contrast, over half of adenocarcinomas originating from breast, uterine cervix and endometrium was negative for 14-3-3s. In these organs (Group 2), only epithelial basal cells expressed 14-3-3s in a manner similar to that of bronchial epithelium (see the following section). Nonpulmonary small cell carcinoma is frequently combined with adenocarcinoma and squamous cell carcinoma. Each portion of these combined tumors (1 in cervix, 1 in bladder and 2 in esophagus) was separately examined. The results confirmed our findings of pulmonary combined small cell carcinoma and NSCLC, and the portion of adeno-or squamous carcinoma, but not small cell carcinoma, was positive for 14-3-3s (Figure 1e ).
14-3-3s expression in normal lung
We examined 14-3-3s expression in fetal and adult tissue to understand the biological role of this protein.
In the developing tissue, 14-3-3s expression was widely distributed throughout epithelial cells, striated and smooth muscles, myocardium and chondrocytes. At gestational weeks 9 and 18, the tracheal epithelium and pulmonary pseudostratified epithelium of the developing lung uniformly expressed 14-3-3s. Signals were also positive in nuclei only in the superficial layer of the epidermis. 
*Organs, from which cancers were derived, are divided according to expression of 14-3-3s in the normal epithelium. Group 1 expressed 14-3-3s uniformly throughout normal epithelium, while expression is restricted to basal cells of epithelium in Group 2. Ad, Adenocarcinoma; Sq, squamous cell carcinoma Down-regulated 14-3-3s expression in neuroendocrine tumors Y Yatabe et al
In adult normal tissue, the distribution of cells expressing 14-3-3s was restricted to a basal portion of the bronchial epithelium, which was identical to the distribution of putative stem cells. To confirm this, we examined the expression of 34bE12 as a marker of basal cell-intermediate filament (Boers et al., 1998; Ramnani and Bostwick, 1999; Verhagen et al., 1992) , p63 as an epithelial stem cell marker (Mills et al., 1999; Pellegrini et al., 2001; Signoretti et al., 2000; Yang et al., 1999) , and p27 as a marker of senescence or differentiation (Endl et al., 2001; Rivard et al., 1996) , in serial sections. The expression of the first two markers was co-localized at cells expressing 14-3-3s, and the expression pattern of p27 and 14-3-3s was contrary to each other (Figure 3a) . These results suggested that 14-3-3s has some relation to stem cell function of the bronchial epithelium. Type II pneumocytes, which are putative progenitors of peripheral parenchyma (Colby et al., 1995) , also expressed 14-3-3s in the peripheral lung. Whereas the expression level is relatively low in the normal state (Figure 3b) , staining was densely positive in hyperplastic type II pneumocytes that reacted to the tissue damage and appeared during repair and regeneration (Figure 3c ). This up- Figure 3 Expression of 14-3-3s and its possible biological role in normal lung. Expression of 14-3-3s (a) overlaps that of p63 and 34bE12 (subset of high-molecular weight keratins), both of which are considered stem cell-associated molecules. Expression of quiescent-associated p27 is contrary to the distribution of 14-3-3s positive cells (a). Type II pneumocytes, which may be progenitor cells in the peripheral lung, express 14-3-3s (b), and expression is dramatically up-regulated when regenerative and/or differentiating drive is activated in tuberculosis (c). Type II pneumocytes reacting to inflammatory damage (" in c) express more 14-3-3s than that at the alveolar septa (? in c). Double fluorescent immunostaining simultaneously demonstrates the distribution of 14-3-3s expressing cells (green signal) and neuroendocrine cells (red signal, ?) in normal bronchial epithelium. These discrete signals indicates that normal neuroendocrine cells showed negligible level of 14-3-3s expression. In contrast, the basal cells are stained in hybrid yellow signals, indicating co-localization of 14-3-3s (green) and keratin (red) expression (e) Down-regulated 14-3-3s expression in neuroendocrine tumors Y Yatabe et al regulation was observed in tissues damaged by common inflammation and by irradiation. Since 14-3-3s was uniformly down-regulated in neuroendocrine tumors, we also examined the expression of 14-3-3s in normal neuroendocrine cells by using double immunostaining. In normal bronchial epithelium, expressions of synaptophysin and 14-3-3s were distinct, in contrast to the merging of 14-3-3s expression with keratin expression (Figure 3d,e) .
Discussion
The present study demonstrated that the expression 14-3-3s is decreased in neuroendocrine tumors. Pulmonary typical carcinoid is characterized by infrequent p53 mutation (Lohmann et al., 1993) , low proliferative activity, fewer genetic alterations (Przygodzki et al., 1996) , and DNA diploidy (Padberg et al., 1996; Przygodzki et al., 1996) . In contrast, SCLC is clinically aggressive, and has frequent p53 mutations (Miller et al., 1992; Takahashi et al., 1991) , high proliferative activity with high apoptotic rates (Brambilla et al., 1996) , inactivation of RB in the G1/S pathway (Salgia and Skarin, 1998), an abnormal G2 checkpoint (Konishi et al., 2001) , and complex karyotypic features (Testa et al., 1997) . Despite these differences, 14-3-3s expression was uniformly decreased among the neuroendocrine tumors examined. Among NSCLC, p53 status (Horio et al., 1993; Mitsudomi et al., 1992; Nishio et al., 1997; Suzuki et al., 1992) , proliferative activity and genetic abnormalities (Yatabe et al., 1998a (Yatabe et al., ,b, 2000 are variable, particularly in pulmonary adenocarcinomas, yet they constantly expressed 14-3-3s. The only feature common to all the cancers with decreased 14-3-3s expression was thus neuroendocrine differentiation. Furthermore, this association was also apparent in neuroendocrine tumors arising from various organs, which was developed through different sequences and mechanisms of carcinogenesis. Our conclusion was further supported by the finding that the decreased expression was restricted to small cell carcinoma portion of the combined small cell carcinoma and ordinary (adeno-or squamous) carcinoma.
One of the biological roles of 14-3-3s in vitro is regulatory function at the G2/M checkpoint through induction by p53 (Chan et al., 1999; Hermeking et al., 1997; Lopez-Girona et al., 1999) . We then examined whether this regulatory role could function in vivo. The expression of 14-3-3s was independent of p53 status in SCLC and LCNEC, and p53 status did not affect 14-3-3s expression in NSCLCs. Apoptotic features were not any more frequent in carcinoid than in NSCLC, although an impaired G2/M checkpoint led to mitotic catastrophe in a cancer cell line (Chan et al., 1999) . Therefore, our results suggested that this constitutive expression of 14-3-3s depended on the other factors rather than p53, and the constitutive expression of 14-3-3s may function differently from induced 14-3-3s that is mediated by p53.
We then considered the significance of decreased 14-3-3s expression in neuroendocrine tumors. Because normal neuroendocrine cells in the bronchial epithelium showed reduced expression of 14-3-3s as shown in Figure 3 , the decreased expression in neuroendocrine tumors may simply reflect the expression status of the normal neuroendocrine cells. However, recent evidences have suggested that carcinoids and SCLC are very different in terms of molecular pathogenesis and putative progenitor cells. Anbazhagan et al. (1999) compared gene expression profiles among normal bronchial epithelium, carcinoid, SCLC and an astrocytic tumor that was derived from the neural crest. The results indicated that the expression profile of SCLC is more closely related to that of bronchial epithelium than to carcinoid tumors. The expression profile of carcinoid tumors had more in common with the neural crest-derived tumors than with SCLC or bronchial epithelium. This implies that carcinoids and SCLC are derived from different progenitor cells, i.e., carcinoids from neuroendocrine cells and SCLC from bronchial epithelium. A recent report (Sturm et al., 2002) supports the idea of different progenitors for carcinoids and SCLC in terms of TTF-1 expression status. Furthermore, combined SCLC and ordinary NSCLC is recognized category as a variant of SCLC , whereas combined carcinoid tumors, that is of carcinoids and SCLC, or of carcinoids and NSCLC, are extremely rare even in the literature. Indeed, in all the cases examined in our study, these combined SCLC and NSCLC, which are clonally related tumors, demonstrated down-regulation of 14-3-3s only in the SCLC portion, but not in that of the NSCLC, as shown in Figure 3 . This implies that the transition involves down-regulation of 14-3-3s, and thus the down-regulation might be required for the development of SCLC.
Little is known about the normal biological role of 14-3-3s. Squamous cell epithelium has abundant 14-3-3s protein (Leffers et al., 1993) , where it promotes the differentiation of squamous epithelium (Dellambra et al., 1995; Pellegrini et al., 2001) . Expression profile analysis has extracted 14-3-3s from a large number of genes, as it is differently expressed in squamous cell carcinomas and adenocarcinomas (Bhattacharjee et al., 2001; Ostergaard et al., 1997) . On the other hand, the expression and function of 14-3-3s in glandular epithelium has remained elusive. The present study revealed that the expression of 14-3-3s in the bronchial epithelium is characteristic, being restricted to the basal cells. This distribution of the expression overlapped with that of 34bE12, p63 and negative p27. The protein 34bE12 is a marker for a subset of high molecular weight keratins; it labels basal cells where cell proliferation is facilitated (Boers et al., 1998; Verhagen et al., 1992) . The p63 protein is required for the morphogenic proliferation of epithelial stem cells, and the development of epidermis, skin appendages, breast, salivary glands and prostate in p63-deficient mice is significantly impaired (Mills et al., 1999; Signoretti et al., 2000; Yang et al., 1999) . The CDK inhibitor, p27 is Down-regulated 14-3-3s expression in neuroendocrine tumors Y Yatabe et al considered to be responsible for the onset and/or maintenance of the quiescent state (Rivard et al., 1996; Zhang et al., 2000) , and only differentiated cells expressed this inhibitor in vivo (Endl et al., 2001) . These findings suggested that 14-3-3s expression has some relation to stem cell function. Furthermore, the up-regulated expression of 14-3-3s in the regenerative state in type II pneumocytes suggested that 14-3-3s is required at activation of the regenerative and/or differentiating drive.
We found that NSCLC usually expressed 14-3-3s, which might simply reflect the expression status of the normal counterpart. Indeed, we observed 14-3-3s expression at metaplastic squamous epithelium and type II pneumocytes, that are putative progenitors of squamous carcinoma and most adenocarcinomas, respectively. Non-uniform expression in breast cancer may also exemplify the reflection. Expression profiling has recently categorized breast cancer as luminal and basal cell types (Gruvberger et al., 2001; Perou et al., 2000; Sorlie et al., 2001 ), and we found that that 14-3-3s was expressed in basal cells but not in superficial cells of normal breast epithelium. An alternative explanation for the constitutive 14-3-3s expression in NSCLC is that it reflects the randomly proliferating nature of common epithelial cancer cells, and that 14-3-3s is required to maintain cancer cell regeneration, like stem cells. However, neuroendocrine tumors also appeared to randomly proliferate despite the decreased expression of 14-3-3s. Such reduced 14-3-3s expression in neuroendocrine tumors may be caused by a different machinery of regeneration and/or differentiation process between neuroendocrine and normal epithelial cells. The neuroendocrine cell lineage was suggested to diverge very early from the course of common epithelial differentiation, and pass through a distinct process, as shown in the model system of intestinal crypts (Gordin, 1989; Simon et al., 1995; Yang et al., 2001) . In general, neuroendocrine tumors rarely show a differentiating feature to certain type of cells, and retain their characteristic morphology. Therefore, 14-3-3s expression status may reflect the machinery of regeneration and/or differentiation.
We reported that hypermethylation is frequent in SCLC cell lines (9 out of 13; 69%), but rare in NSCLC cell lines, except a large cell carcinoma cell line (1 out of 17; 6%) . The present study confirmed that dense methylation of the 14-3-3s gene promoter was associated with decreased 14-3-3s expression in neuroendocrine tumors in vivo as well as in vitro. The 14-3-3s promoter was not methylated in NSCLC cell lines, whereas a mosaic of densely-methylated and non-methylated molecules predominated in vivo, despite intense 14-3-3s expression. For the reason of this mosaic methylation profile, contamination of normal cells could not be neglected. Indeed, methylation was complete in lymph nodes (data not shown), and stromal cells were densely methylated Umbricht et al., 2001) . Alternatively, hemi-allelic methylation might have occurred in NSCLCs. The p53-homolog, p73, is expressed in an allele-specific manner in normal tissue (Kaghad et al., 1997; Nomoto et al., 1998) , and its transcriptional silencing is mediated by DNA methylation (Corn et al., 1999) . The p73 gene is mapped at 1p36, which is near the 14-3-3s gene (1p35.2). Therefore, the methylation profile of the 14-3-3s gene in NSCLCs might reflect hemi-allelic methylation. It is obvious that dense methylation is associated with decreased 14-3-3s expression, because it was highly specific in neuroendocrine tumors. However, complex mechanisms appear to be involved in the regulation of 14-3-3s expression, in addition to promoter hypermethylation, because about half of the neuroendocrine tumors were methylated in a mosaic despite decreased 14-3-3s expression.
In summary, we found that decreased expression of 14-3-3s is a general feature of neuroendocrine tumors. This finding suggested that decreased expression of 14-3-3s is required for neoplastic transformation to develop the neuroendocrine tumors. Furthermore, promoter hypermethylation of 14-3-3s gene was involved in the decreased expression, although other factors appeared to modify the expression. The distribution of the expression in normal tissues implied that 14-3-3s has some association with stem cell functions at activation of the regenerative and/or differentiating drive.
Materials and methods

Patients
We studied a series of 28 patients with pulmonary neuroendocrine tumors, including five of typical carcinoid, two of atypical carcinoid, seven of LCNEC, and 18 of SCLC, from a file of the Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital. Among these, three and seven with LCNEC and SCLC, respectively, have been described (Haruki et al., 2000) . All the neuroendocrine tumors were classified according to the criteria of WHO histological typing of lung and pleural tumors (3rd Ed., in 1999) . The tumor features consisted of abnormal accumulation of p53 in none out of 5, none out of 2, 6 out of 7 and 10 out of 14; lack of RB expression in none out of 5, none out of 2, 5 out of 6 and 12 out of 13; averaged mitotic indices of 1, 12, 57 and 75, in the order of typical carcinoid, atypical carcinoid, LCNEC and SCLC, respectively. We also immunohistochemically analysed three fetal tissues (9 to 18 weeks of gestation) that were obtained at legal, therapeutic abortions or autopsy, and 20 neuroendocrine tumors arising from various organs, listed in Table 2 . We applied a tissue microarray technique to analyse 178 NSCLCs and non-pulmonary, non-neuroendocrine cancers (Kononen et al., 1998) . We evaluated three representative cancer tissue cores per sample (Hoos and Cordon-Cardo, 2001 ). The results obtained with the tissue microarray were verified by comparisons with 50 separate evaluations using corresponding individual whole sections.
Immunohistochemistry
All specimens were 3-mm-thick sections of paraffin-embedded tissue obtained at biopsy or surgery. Immunohistochemical examination proceeded according to the standard avidinDown-regulated 14-3-3s expression in neuroendocrine tumors Y Yatabe et al biotin-peroxidase complex method using monoclonal antibodies against 14-3-3s (N-14, Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA), 34bE12 (DAKO, Copenhagen, Denmark), p63 (4A4, Santa Cruz Biotechnology), and p27 Kip1 (Transduction Laboratory, Lexington, KY, USA). Briefly, deparaffinized sections were immersed in normal swine serum to block non-specific staining for 20 min, and then were incubated with the primary antibodies overnight at 48C. Following sequential incubation with biotinylated secondary antibody and avidin-biotin-peroxidase complex, color was developed with the diaminobenzidine reaction. The sections were washed three times with cold phosphatebuffered saline between incubations. Normal goat serum instead of primary antibody was applied as a negative control. Prior to incubation with the primary antibody, microwave treatment in citrate buffer (pH 6.8) was used for antigen retrieval. Tissues were considered positive for 14-3-3s when staining was equal to or more intense than that of normal epithelium and when over two-thirds of the tumor cells were stained. When 14-3-3s was expressed in two-thirds of the tumors but the staining intensity did not achieve the level of normal positive cells, we scored the case as '+/7'.
For the simultaneous demonstration of 14-3-3s and synaptophysin (a neuroendocrine marker, Novocastra SYNAP-299), fluorescent double staining, using FITClabeled rabbit anti-goat antibody and RPE-labeled rabbit anti-mouse antibody (F0250 and R0270 DAKO, respectively) was applied to three cases of frozen sections of normal bronchial epithelium. For the control experiment, widespectrum keratin was examined, instead of synaptophysin. After sequential incubation of the primary antibodies at room temperature, the sections were rinsed, followed by reaction of the fluorescent-conjugated secondary antibodies for 30 min. The stained sections were examined by BX51-33-FLD2 with an appropriate dual band mirror unit (Olympus, Tokyo, Japan).
Analysis of methylation status
We examined the methylation status of the 14-3-3s promoter in representative cases, including four typical carcinoid, two atypical carcinoid, three LCNEC, four SCLC and 11 NSCLCs. Genomic DNA was microdissected from frozen tissues mounted in O.C.T. compound, to ensure that over 80% of the extract was derived from tumor cells. We then performed bisulfite genomic sequencing as described (Yatabe et al., 2001) . Briefly, converted DNA was amplified with 14-3-3s primer based on the sequence described by Ferguson et al. (2000) , and modified by us. The PCR products contained CpG sites numbered 1 to 9 in the original report (Ferguson et al., 2000) . The primer sequences were: (5'-3') forward-AGTTAGTTTGATTTAGAAGGTTAAGTTGGTAGAGT and reverse-ATACTAAACAACACCCTCCAAACAACCC-TCTAA. Amplified products were cloned (TOPO TA cloning kit, Invitrogen, Carlsbad, CA, USA), and five clones per case were sequenced. The averaged percentage of the CpG sites was considered the methylation status of the case.
Statistical analysis
The w 2 test for independence and unpaired t-test compared incidences of 14-3-3s expression and frequencies of promoter hypermethylation between neuroendocrine and non-neuroendocrine tumors, respectively. A P-value below 0.05 was considered statistically significant.
